C

메디포스트

078160KOSDAQ기초 의약물질 제조업

43.7 / 100

Reference Date: 2026-07-24

Financial Score11.0 / 40
News Sentiment17.7 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, Operating Profit is on a declining trend. Slightly down 4.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Medipost operates three main business segments: umbilical cord blood banking, stem cell therapeutics (Cartistem), and health functional foods. In 2024, the company achieved a record sales revenue of 70.7 billion won, driven by strong performance in its cord blood banking division, which holds the top market share domestically, and its stem cell therapeutics division expanding global clinical trials.

Number of Employees

684people

Average Salary

61.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 25.444.0Point
PBR
1.34Industry Average 1.262.5Point

Higher than industry avg (caution)

ROE
-34.23Industry Average -6.033.5Point

5.7x industry avg (excellent)

Debt Ratio
33.95Industry Average 6.620.0Point

5.1x industry avg (risky)

Trend 2023~20251.0 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲3.6% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼66.6% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -18.2% (declining, 3yr)

Detailed News Sentiment

8 totalPositive 5Neutral 3Negative 0Average Sentiment Score 70.6

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 8,540Won52-week high 28,00052-week low 8,030
1-month return2.0Point

1m -4.47% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral전환가액의조정2026-07-13
  • Neutral전환가액의조정2026-07-06
  • Neutral전환가액의조정2026-06-30